> After discovering impurities in the pills, Ranbaxy Laboratories is recalling 73 million tablets of its epilepsy remedy Gebapentin from the U.S. market. Report
> Bristol-Myers Squibb and partner Otsuka Pharmaceutical said the FDA will fast-track their application to market the antipsychotic Abilify for use in children with bipolar disorder. Report
> India's Orchid Chemicals & Pharmaceuticals got the FDA's nod for its version of the antibiotic Cefpodoxime Proxetil, marketed by Pfizer under the brand name Vantin. Report
> Surgical instruments maker Gyrus was hit with a patent infringement suit by rival ArthroCare. Report
And Finally... Governments meet next week to hammer out a flu-virus sharing agreement so scientists can better track the evolution of H5N1. Report